The Influence of Substance Use on Side Effects of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Psychosis

Bibliographic Data

ID21646174
AuthorsRenata Alisauskiene (Department of Psychiatry, Haukeland University Hospital, Bergen, Norway, corresponding author), Erik Johnsen (0000-0003-0792-4436, Department of Psychiatry, Haukeland University Hospital, Bergen, Norway), Rolf Gjestad (0000-0003-4578-6927, Department of Psychiatry, Haukeland University Hospital, Bergen, Norway), Rune A Kroken (0000-0002-0903-3840, Department of Psychiatry, Haukeland University Hospital, Bergen, Norway), Hugo A Jørgensen (Department of Psychiatry, Haukeland University Hospital, Bergen, Norway), Else‐Marie Løberg (0000-0002-4243-5067, University of Bergen), Else-Marie Løberg (Department of Psychiatry, Haukeland University Hospital, Bergen, Norway)
Year2021
Volume56
Issue12
Pages1880-1891
Publication date2021-10-15
Peer ReviewedYes
Open AccessNo
TypeARTICLE
VenueSubstance Use & Misuse (JOURNAL)
Journal identifiersISSN: 1082-6084 • E-ISSN: 1532-2491
PublisherInforma UK Limited (PUBLISHER • GB)
DOI10.1080/10826084.2021.1958858
PMID34369263
OpenAlexW3190215354
LanguageEN
References cited58

BACKGROUND: Side effects restrict the optimal use of antipsychotics. Little is known about the influence of substance use on side effects. The aim of this study was to compare antipsychotic side effects in patients with psychosis with and without substance use, while also taking medication history and diagnosis into consideration. METHODS: = 226, mean age 34, females 33%) diagnosed with schizophrenia spectrum disorders (SSD; F20-F29) or other psychosis (F30-F32; F10-F19), were treated with olanzapine, quetiapine, risperidone or ziprasidone, and were assessed at baseline, 4-weeks, 14-weeks, and 27-weeks. The UKU-Side Effects Self-Rating Scale version was used to evaluate the side effect profiles, and the information on substance use was based on the Clinician Drug Use Scale. RESULTS: At baseline, 30% of the patients used substances, 54% were diagnosed with SSD, and 47% were antipsychotic naïve. The occurrence of side effects in total was not different in patients with substance use compared to without after 4-weeks of treatment, nor in the follow-up period. At 4-weeks there were some group differences in relation to substance use, diagnosis, and medication history for single side effects. Patients with substance use showed more increased dream activity, less reduced salivation, and more gynecomastia. Patients with SSD showed less neurological side effects, orgasm dysfunction, and tension/inner unrest. The medication naïve patients showed increased hypokinesia/akinesia. CONCLUSION: Substance use alone does not influence the general magnitude of side effects of antipsychotic medication and does not indicate a different prescription practice in patients with psychosis and substance use

Anticholinergic · Antipsychotic · Olanzapine · Psychiatry · Psychosis · Quetiapine · Risperidone · Ziprasidone · Electroconvulsive Therapy Studies · Hallucinations in medical conditions · Medicine · Psychology · Schizophrenia research and treatment · Internal Medicine

Tools

Open DOI